Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 4.9% Higher – Should You Buy?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)’s share price traded up 4.9% on Monday . The stock traded as high as $2.87 and last traded at $2.81. 34,011 shares traded hands during trading, a decline of 35% from the average session volume of 52,642 shares. The stock had previously closed at $2.68.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research note on Monday, April 27th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $10.00.

Kiora Pharmaceuticals Trading Up 4.9%

The business’s 50 day moving average is $2.39 and its two-hundred day moving average is $2.19. The company has a market cap of $12.45 million, a PE ratio of -1.04 and a beta of -0.40.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its earnings results on Friday, May 8th. The company reported ($0.58) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.58).

Institutional Trading of Kiora Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of KPRX. Two Sigma Investments LP bought a new stake in Kiora Pharmaceuticals in the 3rd quarter valued at $33,000. Renaissance Technologies LLC raised its holdings in shares of Kiora Pharmaceuticals by 71.0% during the 4th quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock worth $42,000 after acquiring an additional 8,800 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Kiora Pharmaceuticals during the 3rd quarter valued at approximately $125,000. Alyeska Investment Group L.P. bought a new position in shares of Kiora Pharmaceuticals during the 4th quarter valued at approximately $152,000. Finally, DRW Securities LLC grew its holdings in shares of Kiora Pharmaceuticals by 199.2% in the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after purchasing an additional 73,417 shares in the last quarter. 76.97% of the stock is currently owned by institutional investors.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.